US Stock MarketDetailed Quotes
CVM CEL-SCI
- 0.690
- -0.047-6.40%
Close Dec 13 16:00 ET
- 0.700
- +0.010+1.45%
Post 20:01 ET
44.03MMarket Cap-1.19P/E (TTM)
0.739High0.685Low367.97KVolume0.739Open0.737Pre Close258.83KTurnover0.59%Turnover RatioLossP/E (Static)63.81MShares3.23052wk High5.19P/B42.78MFloat Cap0.49552wk Low--Dividend TTM62.00MShs Float2499.999Historical High--Div YieldTTM7.33%Amplitude0.495Historical Low0.703Avg Price1Lot Size
CEL-SCI Stock Forum
Sign in to post a comment
NOTE: Whenever a stock is up, make sure you check its dilution risk - cash on hand because most likely if they are cash-strapped, they will make offering. Scaling out is key. NEVER listen to those who say hold on because if you lose money, they wouldnt care AT ALL.
*************************************
REVERSE...
*************************************
REVERSE...
56
8
$CEL-SCI (CVM.US)$
CEL-SCI Highlights Biological Rationale for the Use of Multikine in the Confirmatory Registration Head and Neck Cancer Study
Thursday, 12th December at 9:15 am
• Multikine is the first cancer immunotherapy to show pre-surgical tumor regression in head and neck cancer in just 3 weeks - confirmed by pathology at surgery
• Factors supporting the go-ahead for the 212-person registration study in the target population include:
◦ Multikine led to significant rates of tumor reg...
CEL-SCI Highlights Biological Rationale for the Use of Multikine in the Confirmatory Registration Head and Neck Cancer Study
Thursday, 12th December at 9:15 am
• Multikine is the first cancer immunotherapy to show pre-surgical tumor regression in head and neck cancer in just 3 weeks - confirmed by pathology at surgery
• Factors supporting the go-ahead for the 212-person registration study in the target population include:
◦ Multikine led to significant rates of tumor reg...
$VSee Health (VSEE.US)$ $CEL-SCI (CVM.US)$ $SmartKem (SMTK.US)$ $Volato Group (SOAR.US)$ $Onconetix (ONCO.US)$ $Fusion Fuel Green (HTOO.US)$ $SEALSQ Corp (LAES.US)$ $Semtech (SMTC.US)$ $HA Sustainable Infrastructure (HASI.US)$ $Spectral AI (MDAI.US)$ $T Stamp (IDAI.US)$ $ZenaTech (ZENA.US)$ $Poseida Therapeutics (PSTX.US)$
3
3
$CEL-SCI (CVM.US)$ U.S. FDA and CEL-SCI Agree on Use of PD-L1 Biomarker to Select Head and Neck Cancer Patients for Marketing Registration Study to Commence Q1 2025
2 MINUTES AGO, 8:15 AM EST
VIA BUSINESSWIRE
• Biomarker used to select patients who are more likely have favorable outcomes, supporting a successful confirmatory Registration Study
• Patients with low PD-L1 expression treated with Multikine in the target population had a 5-year survival of 73% vs. 45% in the control group in the...
2 MINUTES AGO, 8:15 AM EST
VIA BUSINESSWIRE
• Biomarker used to select patients who are more likely have favorable outcomes, supporting a successful confirmatory Registration Study
• Patients with low PD-L1 expression treated with Multikine in the target population had a 5-year survival of 73% vs. 45% in the control group in the...
2
$CEL-SCI (CVM.US)$
U.S. FDA and CEL-SCI Agree on Use of PD-L1 Biomarker to Select Head and Neck Cancer Patients for Marketing Registration Study to Commence Q1 2025
CEL-SCI (NYSE: CVM) announced FDA agreement on using PD-L1 biomarker for patient selection in its upcoming Multikine Registration Study for head and neck cancer, starting Q1 2025. The study will focus on patients with low PD-L1 tumor expression, following promising results from a previous Phase 3 study where patients showed 73% v...
U.S. FDA and CEL-SCI Agree on Use of PD-L1 Biomarker to Select Head and Neck Cancer Patients for Marketing Registration Study to Commence Q1 2025
CEL-SCI (NYSE: CVM) announced FDA agreement on using PD-L1 biomarker for patient selection in its upcoming Multikine Registration Study for head and neck cancer, starting Q1 2025. The study will focus on patients with low PD-L1 tumor expression, following promising results from a previous Phase 3 study where patients showed 73% v...
3
$CEL-SCI (CVM.US)$
FDA's Oncologic Drugs Advisory Committee Decision on Checkpoint Inhibitors Substantiates Potential of CEL-SCI's Multikine® to Address Major Treatment Gap for PD-L1 Negative Cancer Patients
FDA's Oncologic Drugs Advisory Committee Decision on Checkpoint Inhibitors Substantiates Potential of CEL-SCI's Multikine® to Address Major Treatment Gap for PD-L1 Negative Cancer Patients
$CEL-SCI (CVM.US)$ CEL-SCI Selects Ergomed as CRO as it Gears Up for Confirmatory FDA Registration Study of Multikine® in Head and Neck Cancer
4 MINUTES AGO, 6:00 AM EDT
VIA BUSINESSWIRE
As a clinical research organization (CRO) Ergomed has a strong track record with CEL-SCI in fast enrolment and high quality study delivery
CEL-SCI Corporation (NYSE:CVM) today announced its renewed collaboration with Ergomed Clinical Research for its upcoming U.S. Food and Drug Administration (FDA) confirm...
4 MINUTES AGO, 6:00 AM EDT
VIA BUSINESSWIRE
As a clinical research organization (CRO) Ergomed has a strong track record with CEL-SCI in fast enrolment and high quality study delivery
CEL-SCI Corporation (NYSE:CVM) today announced its renewed collaboration with Ergomed Clinical Research for its upcoming U.S. Food and Drug Administration (FDA) confirm...
$CEL-SCI (CVM.US)$
CEL-SCI’s Multikine® Increased 5-Year Survival Rate to 82.6% in Locally Advanced Resectable Head & Neck Cancer Patients Who Were Deemed to be in the Treatment Group for Surgery and Radiation
CEL-SCI (NYSE American: CVM) reported new data from its Phase 3 study of Multikine® at the ESMO 2024 Congress. The data shows that Multikine increased the 5-year survival rate to 82.6% in locally advanced resectable head and neck cancer patients deemed low risk for recurrence, compared ...
CEL-SCI’s Multikine® Increased 5-Year Survival Rate to 82.6% in Locally Advanced Resectable Head & Neck Cancer Patients Who Were Deemed to be in the Treatment Group for Surgery and Radiation
CEL-SCI (NYSE American: CVM) reported new data from its Phase 3 study of Multikine® at the ESMO 2024 Congress. The data shows that Multikine increased the 5-year survival rate to 82.6% in locally advanced resectable head and neck cancer patients deemed low risk for recurrence, compared ...
$CEL-SCI (CVM.US)$
CEL-SCI to Present New Data for Multikine® Head & Neck Cancer Immunotherapy at the European Society for Medical Oncology 2024 Congress
CEL-SCI (NYSE American: CVM)announced it will present new data from its Phase 3 study of Multikine at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain. The poster, titled 'Prognostic significance of diagnostic staging in treatment naïve, resectable locally advanced primary oral cavity squamous cell carcinoma...
CEL-SCI to Present New Data for Multikine® Head & Neck Cancer Immunotherapy at the European Society for Medical Oncology 2024 Congress
CEL-SCI (NYSE American: CVM)announced it will present new data from its Phase 3 study of Multikine at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain. The poster, titled 'Prognostic significance of diagnostic staging in treatment naïve, resectable locally advanced primary oral cavity squamous cell carcinoma...
CEL-SCI's Phase 3 Population Analysis for Confirmatory Registration Study in Head & Neck Cancer Demonstrates Well-Balanced Patient Population and Confidence in Clinical Results.
Head and neck cancers (HNC) remain a global health challenge, impacting thousands of individuals each year. Advances in immunotherapy have offered new hope for improving patient outcomes, particularly concerning survival rates. In this context...
Head and neck cancers (HNC) remain a global health challenge, impacting thousands of individuals each year. Advances in immunotherapy have offered new hope for improving patient outcomes, particularly concerning survival rates. In this context...
No comment yet
Heat List
US
Overall
Symbol
Price
% Chg
No Data
Den the Dragon : Good
my friend
李飞538 : Thank you for your daily dedication.
101726747 : ty
Den the Dragon : hit
Phuong999 : Thank you
View more comments...